Global Inhibition of Reactive Oxygen Species (ROS) Inhibits Paclitaxel-Induced Painful Peripheral Neuropathy by Fidanboylu, Mehmet et al.
Global Inhibition of Reactive Oxygen Species (ROS)
Inhibits Paclitaxel-Induced Painful Peripheral
Neuropathy
Mehmet Fidanboylu
¤, Lisa A. Griffiths, Sarah J. L. Flatters*
Wolfson Centre for Age-Related Diseases, Centre for Integrative Biomedicine, King’s College London, London, United Kingdom
Abstract
Paclitaxel (TaxolH) is a widely used chemotherapeutic agent that has a major dose limiting side-effect of painful peripheral
neuropathy. Currently there is no effective therapy for the prevention or treatment of chemotherapy-induced painful
peripheral neuropathies. Evidence for mitochondrial dysfunction during paclitaxel-induced pain was previously indicated
with the presence of swollen and vacuolated neuronal mitochondria. As mitochondria are a major source of reactive oxygen
species (ROS), the aim of this study was to examine whether pharmacological inhibition of ROS could reverse established
paclitaxel-induced pain or prevent the development of paclitaxel-induced pain. Using a rat model of paclitaxel-induced pain
(intraperitoneal 2 mg/kg paclitaxel on days 0, 2, 4 & 6), the effects of a non-specific ROS scavenger, N-tert-Butyl-a-
phenylnitrone (PBN) and a superoxide selective scavenger, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL) were
compared. Systemic 100 mg/kg PBN administration markedly inhibited established paclitaxel-induced mechanical
hypersensitivity to von Frey 8 g and 15 g stimulation and cold hypersensitivity to plantar acetone application. Daily
systemic administration of 50 mg/kg PBN (days 21 to 13) completely prevented mechanical hypersensitivity to von Frey 4 g
and 8 g stimulation and significantly attenuated mechanical hypersensitivity to von Frey 15 g. Systemic 100 mg/kg TEMPOL
had no effect on established paclitaxel-induced mechanical or cold hypersensitivity. High dose (250 mg/kg) systemic
TEMPOL significantly inhibited mechanical hypersensitivity to von Frey 8 g & 15 g, but to a lesser extent than PBN. Daily
systemic administration of 100 mg/kg TEMPOL (day 21 to 12) did not affect the development of paclitaxel-induced
mechanical hypersensitivity. These data suggest that ROS play a causal role in the development and maintenance of
paclitaxel-induced pain, but such effects cannot be attributed to superoxide radicals alone.
Citation: Fidanboylu M, Griffiths LA, Flatters SJL (2011) Global Inhibition of Reactive Oxygen Species (ROS) Inhibits Paclitaxel-Induced Painful Peripheral
Neuropathy. PLoS ONE 6(9): e25212. doi:10.1371/journal.pone.0025212
Editor: Mark L. Baccei, University of Cincinnatti, United States of America
Received July 4, 2011; Accepted August 30, 2011; Published September 26, 2011
Copyright:  2011 Fidanboylu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: SJLF is an Academic Fellow and MF and LAG are postgraduate students in the Centre for Integrative Biomedicine. Their positions and these studies are
supported by a Capacity Building Award in Integrative Mammalian Biology funded by the Biotechnology and Biological Sciences Research Council (BBSRC), British
Pharmacological Society (BPS) Integrative Pharmacology Fund, Higher Education Funding Council for England (HEFCE), Medical Research Council (MRC), Scottish
Funding Council (SFC) and the Department for Innovation, Universities and Skills (DIUS). These studies are also partly funded by the Wellcome Trust. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sarah.flatters@kcl.ac.uk
¤ Current address: Institute of Pharmaceutical Sciences, Centre for Integrative Biomedicine, King’s College London, London, United Kingdom
Introduction
Paclitaxel is a taxane-derived chemotherapeutic used alone, or
in combination therapy, for the treatment of ovarian, breast and
advanced non-small cell lung cancers, and AIDS-related Kaposi’s
sarcoma. Paclitaxel binds to b-tubulin of microtubules [1],
stabilising microtubules and interfering with spindle-microtubule
dynamics, arresting mitosis and inducing apoptosis [2]. Painful
peripheral neuropathy is the major dose-limiting side-effect of
paclitaxel therapy. Patients describe various sensory symptoms
including mechanical allodynia, spontaneous pain, cold allodynia,
numbness, tingling, in a ‘stocking and glove’ distribution [3,4,5].
Emergence of these symptoms can mean that patients cannot
complete optimal chemotherapy schedules [6] thus potentially
limiting anti-cancer actions. The incidence and severity of
paclitaxel-induced pain symptoms correlates with increasing
cumulative doses of paclitaxel [7,8]. Following the cessation of
paclitaxel, pain and sensory abnormalities can persist for months
or years [5,9]. Currently, there is no effective therapy for the
prevention or treatment of chemotherapy-induced painful periph-
eral neuropathy. Several analgesics with established efficacy in
other painful neuropathies have failed to show any efficacy in
double-blinded, placebo-controlled trials of patients with chemo-
therapy-induced painful peripheral neuropathy [10,11,12,13].
Reactive oxygen species (ROS) e.g. superoxide radical O2
2,
hydroxyl radical OH
., are by-products of oxidative phosphoryla-
tion and usually decomposed by specialised cellular enzymes
e.g.superoxide dismutases, peroxidases. In the 1990s, the role of
ROS in neuropathic pain was demonstrated with the inhibition of
CCI-evoked heat hyperalgesia by novel antioxidants 4-hydroxy-
2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL) [14], N-acetyl-
cysteine [15] and tirilazad [16] and increased superoxide
dismutase levels in the axotomised sciatic nerve [17]. More
recently, pharmacological inhibition of ROS was reported to have
anti-nociceptive effects in neuropathic and inflammatory pain
models. N-tert-Butyl-a-phenylnitrone (PBN), a non-specific ROS
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nerve ligation (SNL) [18,19,20], capsaicin-induced inflammation
[21,22] and visceral inflammation [23]. Other non-specific ROS
scavengers, 5,5-dimethylpyrroline-N-oxide and nitrosobenzene
also relieved neuropathic pain behaviours [18]. Reagents that
mimic superoxide dismutase activity (thus specifically scavenging
superoxide), inhibited hypersensitivity to mechanical/heat stimuli
evoked by either peripheral nerve injury [14,20] or inflammation
[21,22,24,25]. Furthermore, mitochondrial ROS-producing pro-
files are increased in the spinal cord following peripheral nerve
injury [26] or an inflammatory stimulus [22,27].
Our interest in the role of ROS in chemotherapy-induced pain
developed after finding swollen/vacuolated mitochondria in
peripheral sensory nerves of paclitaxel-treated rats, in the absence
of axonal degeneration [28]. These atypical changes in neuronal
mitochondria correlated with the paclitaxel-induced pain time
course i.e. present during the pain syndrome but not at its
resolution [28]. Considering that mitochondria are a major source
of ROS as a by-product of oxidative phosphorylation, we
examined the potential causal role of ROS in chemotherapy-
induced painful peripheral neuropathy. Here we compare the
effects of systemic administration of two ROS scavengers with
differing selectivity, PBN and TEMPOL, on paclitaxel-induced
pain. Using a rat model of paclitaxel-induced pain, we assess the
ability of PBN, a non-specific ROS scavenger and TEMPOL, a
superoxide dismutase mimetic, to a) inhibit established paclitaxel-
induced pain and b) counteract the development of paclitaxel-
induced pain.
Methods
All experiments were carried out in strict accordance with the
UK Animals (Scientific Procedures) Act 1986 and the ethical
guidelines issued by the International Association for the Study of
Pain [29]. The protocol was approved by the Ethical Review Panel
of King’s College London and conducted under the UK Home
Office project license 70/6673. Adult male Sprague-Dawley rats
(starting weight 180–220 g, Harlan/Charles-River, UK) were
housed in groups of 3–4 on sawdust bedding in plastic cages with
environmental enrichment materials. Artificial lighting was
provided on a fixed 12 h light/12 h dark cycle (7am lights on)
with food and water available ad libitum. Bedding/cages were
changed twice a week and only rats were housed in the same
room. Prior to any behavioural testing, rats were habituated to the
testing environment for 30 minutes on two or three separate days.
2.1 Administration of paclitaxel
Following habituation to the behavioural testing environment
and baseline measurements of mechanical sensitivity (see Section
2.2), rats were injected intraperitoneally (i.p.) with 2 mg/kg
paclitaxel on four alternate days (days 0, 2, 4 and 6) as previously
described [28,30,31,32]. 2 mg/ml paclitaxel was prepared with
sterile 0.9% saline for injection (Fresenius Kabi, UK) from the
clinical formulation of 6 mg/ml Paclitaxel Concentrate for
Solution for Infusion (CP Pharmaceuticals Ltd, UK).
2.2 Behaviouralassessment of mechanical hypersensitivity
Animals were placed on an elevated platform of small metal
rods (spaced 8 mm apart) in individual Perspex boxes (dimensions
15 cm616 cm621 cm). Animals were allowed to acclimatise for
5–10 minutes before testing. Mechanical hypersensitivity was
assessed using three von Frey filaments with bending forces of
4 g, 8 g and 15 g, in ascending order of force, as previously
described [28,31,32]. Each application of a von Frey filament to
the hind paw was held for five seconds and each hind paw was
stimulated five times with each of the three von Frey filaments.
The application of each filament was varied within the mid-
plantar area to avoid stimulating the footpads or the same spot
twice. Withdrawal responses to the von Frey filaments from both
hind paws were counted and combined to give an overall
percentage response, e.g. if a rat withdrew to 4 out of the10
applications of von Frey 8 g, this was recorded as 40% overall
response to von Frey 8 g for that rat. All testing was performed on
rats when they were alert, not grooming and with all four paws in
contact with the platform. Following habituation, three baseline
measurements of mechanical sensitivity were taken prior to
paclitaxel administration and averaged.
2.3 PBN experiments on mechanical hypersensitivity
N-tert-Butyl-a-phenylnitrone (PBN, Sigma-Aldrich, UK) was
dissolved in sterile 0.9% saline for injection (Fresenius Kabi, UK)
resulting in a clear, colourless solution. PBN was administered
intraperitoneally (i.p.) in either a treatment or prophylactic dosing
paradigm, to test if PBN could treat established paclitaxel-induced
pain or prevent the development of paclitaxel-induced pain.
Treatment dosing paradigm. Following habituation and
baseline testing, all rats received paclitaxel as described above and
the emergence of mechanical hypersensitivity was monitored. On
day 26 post paclitaxel initiation, von Frey testing was performed
on all rats and rats were then divided into two groups displaying
similar levels of mechanical hypersensitivity. Rats then received an
i.p. injection of 100 mg/kg PBN (n=9) or an equivalent volume of
vehicle (sterile 0.9% saline, n=9). Rats were tested again for
mechanical hypersensitivity at one hour, three hours and 24 hours
following PBN/vehicle administration. This process was repeated
for the next two consecutive days i.e. Day 27 & Day 28 post
paclitaxel treatment. Thus rats with established paclitaxel-induced
mechanical hypersensitivity received either three daily injections of
100 mg/kg PBN or saline, with each injection followed 1, 3 and
24 hours later by von Frey testing. Throughout the experiment,
behavioural testing was performed under blind conditions by a
single experimenter (MF). Injections were performed by another
scientist. PBN/vehicle treatments were randomised within the
equal groups of 6 animals being tested in a given session. These
methods provided a concurrent vehicle-treated group throughout
the experiments to control for potential variety in behavioural
response due to the time of day. Following completion of the
experiment, the identity of the treatment received by each rat was
revealed and the data analysed.
Prophylactic dosing paradigm. Following habituation and
four baseline measurements, rats were divided into two groups
based on their responses to von Frey stimulation providing two
groups with similar average baseline mechanical sensitivity. Rats
received daily i.p. doses of either 50 mg/kg PBN (n=8) or an
equivalent volume of vehicle (sterile 0.9% saline, n=8) for 15
consecutive days (day -1 through to day 13). On days 0, 2, 4 & 6
when paclitaxel was also administered, rats received PBN/vehicle
injection before the paclitaxel injection. 50 mg/kg PBN was used
in this experiment as opposed to 100 mg/kg due to concerns over
tolerability to large injection volumes during an extended period.
Mechanical sensitivity was then assessed in the mornings on days
7, 10, 14, 17, 19, 21, 25, 28, 31, 34, 38, 41 and 45 following the
initiation of paclitaxel treatment (day 0). Throughout the
experiment, behavioural testing and PBN/vehicle administration
was performed under blind conditions by a single experimenter
(MF). Following completion of the experiment, the identity of the
treatment received by each rat was revealed and the data analysed.
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4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL,
Sigma-Aldrich, UK) dissolved in sterile 0.9% saline for injection
(Fresenius Kabi, UK) resulting in an orange solution. TEMPOL
was administered intraperitoneally (i.p.) in either a prophylactic or
treatment dosing paradigm to test if TEMPOL could treat
established paclitaxel-induced pain or prevent the development of
paclitaxel-induced pain.
Treatment dosing paradigm. Following habituation and
baseline testing, all rats received paclitaxel as described above and
the emergence of mechanical hypersensitivity was monitored. On
day 27 post paclitaxel initiation, von Frey testing was performed
on all rats and rats were then divided into three groups displaying
similar levels of mechanical hypersensitivity. Rats then received an
i.p. injection of either 100 mg/kg TEMPOL (n=8), 250 mg/kg
TEMPOL (n=8) or an equivalent volume of vehicle (sterile 0.9%
saline, n=8). Rats were tested again for mechanical
hypersensitivity at one hour, three hours and 24 hours following
TEMPOL/vehicle administration. Throughout the experiment,
behavioural testing was performed under blind conditions by a
single experimenter (SJLF). Injections were performed by another
scientist. TEMPOL/vehicle treatments were randomised within
the equal groups of 8 animals being tested in a given session. These
methods provided a concurrent vehicle-treated group throughout
the experiments to control for potential variety in behavioural
response due to the time of day. Following completion of the
experiment, the identity of the treatment received by each rat was
revealed and the data analysed. Initially this TEMPOL treatment
dosing paradigm was intended to run over three consecutive days
(as performed for PBN). However due to significant side-effects
(ptosis, pilorection, fits, and catatonia) observed immediately
following 250 mg/kg administration the experiment was
curtailed. These side-effects were not evident at the one hour
testing time point.
Prophylactic dosing paradigm. In the prophylactic
paradigm, following habituation and baseline testing, rats were
divided into two groups based on their responses to von Frey
stimulation providing two groups with similar baseline mechanical
sensitivity. Rats received daily i.p. doses of either 100 mg/kg
TEMPOL (n=9) or an equivalent volume of vehicle (sterile 0.9%
saline, n=9) for 14 consecutive days (day 21 through to day 12).
On days 0, 2, 4 & 6 when paclitaxel was also administered, rats
received TEMPOL/vehicle injection before the paclitaxel
injection. Mechanical sensitivity was then assessed in the
mornings on days 7, 13, 17, 20, 24, 27, 33, 39 and 45 following
the initiation of paclitaxel treatment (day 0). Throughout the
experiment, behavioural testing and TEMPOL/vehicle
administration was performed under blind conditions by a single
experimenter (SJLF). Following completion of the experiment, the
identity of the treatment received by each rat was revealed and the
data analysed. As TEMPOL dissolved to give an orange solution,
blinding procedures were more challenging than in PBN
experiments. KCL Biological Services Unit staff kept SJLF blind
to treatment received by randomisation of rat order within the
elevated testing environment (at day 7) and by renumbering rats
from day 12 onwards.
2.5 Behavioural assessment of cold hypersensitivity
Animals were placed on an elevated platform of small metal
rods (spaced 8 mm apart) in individual Perspex boxes (dimensions
15 cm616 cm621 cm). Animals were allowed to acclimatise for
5–10 minutes before testing. Cold hypersensitivity was assessed
using acetone, as previously described [31]. 50 ml of acetone was
applied to the plantar surface of the hind paw using a Gilson P200
pipette and a stopwatch was started. In the following 20 seconds
after acetone application the rat’s response was monitored. If the
rat did not withdraw, flick or stamp its paw within this 20-sec
period then no response was recorded for that trial (0 points see
below). However, if within this 20-sec period the animal responded
to the cooling effect of the acetone, then the animal’s response was
assessed for an additional 20 seconds, a total of 40 seconds from
initial application. Responses to acetone were graded to the
following 4-point scale: 0=no response, 1=quick withdrawal,
flick or stamp of the paw, 2=prolonged withdrawal or repeated
flicking ($3) of the paw, 3=repeated flicking of the paw with
licking directed at the ventral side of the paw. Acetone was applied
alternately three times to each paw and the responses scored
categorically. At least 12 minutes had elapsed before the next
application of acetone was applied to the same hind paw.
Cumulative scores were then generated by adding the 6 scores
for each rat together, the minimum score being 0 (no response to
any of the 6 trials) and the maximum possible score being 18
(repeated flicking and licking of paws on each of the 6 trials). All
testing was performed on rats when they were alert, not grooming
and with all four paws in contact with the platform.
2.6 TEMPOL/PBN experiment on cold hypersensitivity
Following habituation and baseline testing, 24 rats received
paclitaxel as described above and the emergence of cold
hypersensitivity was monitored. Due to time constraints, this
experiment using 24 rats was conducted on two separate days. On
day 27 post paclitaxel initiation, acetone testing was performed on
15 rats and rats were then divided into three groups (n=5)
displaying similar levels of cold hypersensitivity. Rats then received
an i.p. injection of either 100 mg/kg PBN, 100 mg/kg TEMPOL
or an equivalent volume of vehicle (sterile 0.9% saline). Rats were
tested again for cold hypersensitivity at one hour, three hours and
24 hours following PBN/TEMPOL/vehicle administration. On
day 30 post paclitaxel initiation, acetone testing was performed on
the remaining 9 rats and rats were then divided into three groups
(n=3) displaying similar levels of cold hypersensitivity. Similarly,
rats then received an i.p. injection of either 100 mg/kg PBN,
100 mg/kg TEMPOL or an equivalent volume of vehicle (sterile
0.9% saline). Rats were tested again for cold hypersensitivity at
one hour, three hours and 24 hours following PBN/TEMPOL/
vehicle administration. Throughout the experiment, behavioural
testing was performed under blind conditions by a single
experimenter (LAG). Injections were performed by another
scientist. PBN/TEMPOL/vehicle treatments were randomised
within the groups of animals (7–9) being tested in a given session.
These methods provided a concurrent vehicle-treated group
throughout the experiments to control for potential variety in
behavioural response due to the time of day for example.
Following completion of the experiment, the identity of the
treatment received by each rat was revealed and the data pooled
from each part of the experiment resulting in n=8 for each
treatment group.
2.7 Statistics
One tailed unpaired t-tests with Bonferroni correction were
used to compare the effects of repeated PBN treatment to vehicle
treatment on established paclitaxel-induced mechanical hypersen-
sitivity (Fig. 1). One way, repeated measures, analysis of variance
(ANOVA) followed by Dunnett’s post hoc analysis was used to test
for significant development of paclitaxel-induced mechanical
hypersensitivity following prophylactic administration of PBN/
vehicle (Fig. 2). One tailed unpaired t-tests with Bonferroni
correction were also used to compare prophylactic PBN-treated
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responses (Fig. 2C). One way ANOVA with Tukey-Kramer post
hoc analysis was used to compare effects of 100 mg/kg & 250 mg/
kg TEMPOL to concurrent vehicle-treated group on established
paclitaxel-induced mechanical hypersensitivity (Fig. 3). One way,
repeated measures, analysis of variance (ANOVA) followed by
Dunnett’s post hoc analysis was used to test for significant
development of paclitaxel-induced mechanical hypersensitivity
following prophylactic administration of TEMPOL/vehicle
(Fig. 4). Kruskal-Wallis test with Dunn’s multiple comparisons
post hoc analysis was used to compare effects of PBN and
TEMPOL to the concurrent vehicle-treated group on established
paclitaxel-induced cold hypersensitivity (Fig. 5). Statistical signif-
icance was accepted at p,0.05. No distinction has been made
when p,0.01 or p,0.001 and is denoted on figures as p,0.05.
Results
A cumulative dose of 8 mg/kg paclitaxel administered in four
i.p. injections resulted in significant mechanical and cold
hypersensitivity, assessed by responses to von Frey 4 g, 8 g and
15 g stimulation and acetone application, respectively. Maximal
mechanical hypersensitivity was observed around day 27 post
paclitaxel initiation as previously described [28]. Figure 1 shows
the effect of repeated systemic 100 mg/kg PBN administration on
maximal paclitaxel-induced mechanical hypersensitivity. Respons-
es to von Frey 4 g were unaffected by PBN treatment throughout
the experiment (Fig. 1A). In contrast, PBN significantly inhibited
responses to von Frey 8 g & 15 g, by 52%–73%, at one and three
hours following the first injection compared to the concurrent
vehicle treated group at those time points (p,0.05, Figs. 1B&C,
one-tailed unpaired t-tests with Bonferroni correction). Subsequent
systemic PBN administration on the following two days also
significantly inhibited responses to von Frey 8 g & 15 g one hour
post injection only by 19% and 40%, respectively, compared to
the concurrent vehicle treated group at that time point (p,0.05,
Figs. 1B&C, one-tailed unpaired t-tests with Bonferroni correc-
tion). This smaller inhibitory effect on repeated dosing could
indicate a degree of tolerance to systemic PBN treatment. Pre-
paclitaxel responses to von Frey stimulation, in the rats used in this
experiment, were very similar to those responses shown in Figure 2
(Pre Pacl.).
Prophylactic PBN administration before, during and after
paclitaxel administration (50 mg/kg daily, day 21 through to
day 13) had a marked preventative effect on the development of
paclitaxel-induced mechanical hypersensitivity (Figure 2). No
significant increase was observed in the responses to von Frey
4 g & 8 g of rats that received PBN treatment at any time point
compared to pre-paclitaxel readings (Fig. 2 A&B, one-way
repeated measures ANOVA with Dunnett’s post hoc analysis).
In comparison, a progressive increase in von Frey 4 g & 8 g
responses was seen in vehicle-treated rats that were statistically
significant from day 19 and 25, respectively, compared to pre-
paclitaxel readings (p,0.05, Fig. 2 A&B, one-way repeated
measures ANOVA with Dunnett’s post hoc analysis). Responses
to von Frey 15 g were significantly increased compared to pre-
paclitaxel levels in rats that had received either PBN or vehicle
over the time course (p,0.05, Fig. 2C, one-way repeated measures
ANOVA with Dunnett’s post hoc analysis). However, the
magnitude of paclitaxel-evoked increase in overall response to
von Frey 15 g in relation to pre-paclitaxel responses was 32% in
the PBN group compared to 48% in the vehicle group.
Furthermore, significant hypersensitivity to von Frey 15 g in the
vehicle group was first observed at day 10 and present for 12 of 13
time points, whereas in the PBN group it was first observed at day
17 and present for 7 of 13 time points (Fig. 2C). Direct statistical
comparison of von Frey 15 g responses between prophylactic
vehicle and PBN administration showed that PBN caused a
significant attenuation at day 31, 38 and 45 (p,0.05, one-tailed
unpaired t-tests with Bonferroni correction).
Given these inhibitory effects on paclitaxel-induced pain of
global ROS inhibition by PBN, we investigated whether these
inhibitory effects could be replicated with selective inhibition of
superoxide radicals (O2
2) using TEMPOL, a superoxide dis-
mutase mimetic. Figure 3 shows the effects of systemic 100 mg/kg
and 250 mg/kg TEMPOL on maximal paclitaxel-induced
mechanical hypersensitivity. 100 mg/kg TEMPOL had no effect
on responses to 4 g, 8 g or 15 g von Frey stimulation either at one
hour, three hours or 24 hours post injection (Fig. 3, one-way
ANOVA with Tukey-Kramer post hoc analysis). Similarly, von
Frey 4 g responses were unaffected by 250 mg/kg TEMPOL.
However, 250 mg/kg TEMPOL significantly inhibited responses
to von Frey 8 g & 15 g at one hour post injection by 38% and
41%, respectively, compared to the concurrent vehicle-treated
group (p,0.05, Fig. 3, one-way ANOVA with Tukey-Kramer post
hoc analysis). Side-effects were observed 1–5 minutes following
250 mg/kg TEMPOL administration; all rats showed ptosis, 6 of 8
rats were markedly subdued and 3 of 8 rats showed jerking
movements and shaking. There was no evidence of these effects
during von Frey testing at one, three or 24 hours post
administration. However additional days of dosing such as those
in the PBN experiment were not performed due to concerns
regarding tolerability to repeated 250 mg/kg TEMPOL dosing.
The effects of prophylactic TEMPOL administration before,
during and after paclitaxel administration (100 mg/kg daily, day
21 through to day 12) are illustrated in Figure 4. A significant
mechanical hypersensitivity to von Frey 4 g, 8 g & 15 g
stimulation developed in both TEMPOL and vehicle-treated
groups in a similar manner. A significantly increased response to
von Frey 4 g stimulation was observed from day 20 onwards, in
TEMPOL and vehicle-treated groups, comparing to pre-paclitaxel
response levels (p,0.05, Fig. 4A, one-way repeated measures
ANOVA with Dunnett’s post hoc analysis). Significantly increased
responses to von Frey 8 g & 15 g stimulation were observed from
day 13 onwards, in TEMPOL and vehicle-treated groups,
comparing to pre-paclitaxel response levels (p,0.05, Fig. 4B&C,
one-way repeated measures ANOVA with Dunnett’s post hoc
analysis). There was no significant difference in responses to von
Frey stimulation following prophylactic TEMPOL or vehicle
administration, at any time point.
Paclitaxel is also known to induce cold hypersensitivity in
humans [5] and rats [31]. Therefore we assessed the effects of PBN
and TEMPOL on established paclitaxel-induced cold hypersen-
sitivity to compare to their effects on mechanical hypersensitivity.
Figure 5 shows the effects of systemic 100 mg/kg PBN and
100 mg/kg TEMPOL on maximal paclitaxel-induced cold
hypersensitivity. PBN significantly inhibited responses to acetone
application at one and three hours post administration compared
to vehicle administration (p,0.05, Figure 5, Kruskal-Wallis test
with Dunn’s multiple comparisons post hoc analysis). In contrast,
TEMPOL had no effect on paclitaxel-induced cold hypersensitiv-
ity.
Discussion
In this study, we have examined the role of ROS in the
maintenance and development of paclitaxel-induced painful
peripheral neuropathy in vivo. We have observed the effects of
Role of ROS in Paclitaxel-Induced Pain Behaviours
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25212Figure 1. Effect of repeated PBN dosing on established paclitaxel-induced mechanical hypersensitivity. A–C show the effect of
repeated systemic 100 mg/kg PBN or vehicle administration on behavioural responses to von Frey 4 g, 8 g and 15 g stimulation, respectively, on
days 26, 27 & 28 following paclitaxel initiation. Graphs show the mean 6 SEM of response frequency to mechanical stimulation after paclitaxel but
before PBN/vehicle injection (Post Pacl./Pre inj.), and then following single doses of PBN/vehicle on consecutive days (1 h, 3 h and 24 h after PBN/
vehicle injection). *p,0:05; one-tailed, unpaired t-tests with Bonferroni correction comparing PBN treatment to vehicle treatment at each time points,
n=9 per group.
doi:10.1371/journal.pone.0025212.g001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25212Figure 2. Effect of prophylactic PBN on the development of paclitaxel-induced mechanical hypersensitivity. Systemic 50 mg/kg PBN or
vehicle was administered once daily for 15 consecutive days (day 21 through to day 13) with systemic paclitaxel administration occurring on days 0,
2, 4 & 6. Graphs show the mean 6 SEM of the response frequency to mechanical stimulation by A) von Frey 4 g, B) von Frey 8 g and C) von Frey 15 g
before paclitaxel (Pre Pacl.) and up to day 45 post-paclitaxel initiation. *p,0.05; one-way, repeated measures ANOVA with Dunnett’s post hoc analysis
compared to pre-paclitaxel readings, n=8 per group. NB: The asterisks indicate the occurrence of significant paclitaxel-induced mechanical
hypersensitivity.
doi:10.1371/journal.pone.0025212.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25212Figure 3. Effect of TEMPOL on established paclitaxel-induced mechanical hypersensitivity. A–C show the effect of systemic 100 mg/kg
TEMPOL, 250 mg/kg TEMPOL or vehicle administration on behavioural responses to von Frey 4 g, 8 g and 15 g stimulation, respectively, on day 27
following paclitaxel initiation. Graphs show the mean 6 SEM of response frequency to mechanical stimulation after paclitaxel but before TEMPOL/
vehicle injection (Post Pacl./Pre inj.), and then 1, 3 and 24 hours following TEMPOL/vehicle administration. *p,0:05; one-way ANOVA with Tukey-
Kramer post hoc analysis, n=8 per group.
doi:10.1371/journal.pone.0025212.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25212Figure 4. Effect of prophylactic TEMPOL on the development of paclitaxel-induced mechanical hypersensitivity. Systemic 100 mg/kg
TEMPOL or vehicle was administered once daily for 14 consecutive days (day 21 through to day 12) with systemic paclitaxel administration occurring
on days 0, 2, 4 & 6. Graphs show the mean 6 SEM of the response frequency to mechanical stimulation by A) von Frey 4 g, B) von Frey 8 g and C) von
Frey 15 g before paclitaxel (Pre Pacl.) and up to day 45 post-paclitaxel initiation. *p,0.05; one-way, repeated measures ANOVA with Dunnett’s post
hoc analysis compared to pre-paclitaxel readings, n=9 per group. NB: The asterisks indicate the occurrence of significant paclitaxel-induced
mechanical hypersensitivity.
doi:10.1371/journal.pone.0025212.g004
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and a superoxide-specific scavenger, TEMPOL, in both treatment
and prophylactic dosing paradigms. The rationale for these
experiments was to test if PBN and/or TEMPOL could reverse
established paclitaxel-induced pain and/or prevent the develop-
ment of paclitaxel-induced pain, as both scenarios have significant
clinical relevance.
The first administration of PBN markedly inhibited established
paclitaxel-induced mechanical hypersensitivity to von Frey 8 g
and 15 g stimulation for over three hours. Similarly, repeated
bolus PBN treatment on the following two days also significantly
inhibited this mechanical hypersensitivity, but to a lesser extent,
perhaps indicating tolerance to repeated PBN administration.
Mechanical hypersensitivity to von Frey 4 g was unaffected by
PBN treatment, which could suggest a lack of anti-allodynic effect
by PBN or the relatively small window of hypersensitivity to von
Frey 4 g in this cohort of rats to elicit a statistically significant
inhibition. PBN also significantly inhibited paclitaxel-induced cold
hypersensitivity. In comparison, prophylactic PBN dosing com-
pletely prevented the development of mechanical hypersensitivity
to von Frey 4 g & 8 g stimulation through to day 45 post paclitaxel
initiation. Prophylactic PBN dosing also delayed the appearance
of, and reduced the magnitude of mechanical hypersensitivity to
von Frey 15 g. These effects demonstrate that ROS play a role in
both the maintenance and development of paclitaxel-induced
pain.
The effects of TEMPOL on paclitaxel-induced mechanical
hypersensitivity we observed were quite different to the inhibitory
effects of PBN. The same dose of TEMPOL (100 mg/kg) did not
inhibit established paclitaxel-induced mechanical hypersensitivity.
High dose (250 mg/kg) TEMPOL inhibited mechanical hyper-
sensitivity to von Frey 8 g and 15 g at one hour, but to a lesser
extent than observed with PBN and these effects were not present
at three hours post administration. Similar to PBN, TEMPOL had
no effect on established mechanical hypersensitivity to von Frey
4 g. However, in marked contrast to PBN, prophylactic TEMPOL
showed no inhibitory effects on the development of paclitaxel-
induced mechanical hypersensitivity through to day 45 post
paclitaxel initiation. Prophylactic TEMPOL was administered at
twice the prophylactic PBN dose that prevented development of
paclitaxel-induced mechanical hypersensitivity. It is possible that
higher doses of TEMPOL may have an inhibitory effect on the
development of paclitaxel-induced pain. However, given the side-
effects observed in the minutes following 250 mg/kg TEMPOL
administration in the established pain study, we decided that
100 mg/kg was the maximally tolerated dose for repeated
prophylactic dosing. The overall lack of effect of TEMPOL in
this study suggests that superoxide radicals do not play a role in the
maintenance or development of paclitaxel-induced pain. The lack
of parallel effects of PBN and TEMPOL in paclitaxel-induced
pain provides further evidence that chemotherapy-induced painful
peripheral neuropathies have different causal mechanisms to other
pain states. Previously, both PBN and TEMPOL at similar doses
have been shown to inhibit SNL-evoked heat and mechanical
hypersensitivity in a similar manner [20]. Furthermore, both PBN
and TEMPOL inhibited capsaicin-induced secondary hyperalge-
sia when administered systemically before or after capsaicin
administration [22].
A recent study has examined the effects of PBN on paclitaxel-
induced mechanical hypersensitivity [33]. These authors used the
same dosing schedule of paclitaxel (2 mg/kg i.p. on days 0, 2, 4 &
6) as used in this study, although the paclitaxel was dissolved in a
vehicle solution of DMSO, Tween 80 and saline as opposed to the
clinical formulation (Cremophor EL, ethanol and saline) used
here. On established paclitaxel-induced mechanical hypersensitiv-
ity they found, as we report here, inhibitory effects following single
and repeated systemic administration of 100 mg/kg PBN. They
also examined prophylactic PBN dosing paradigms on the
development of paclitaxel-induced mechanical hypersensitivity.
Daily 200 mg/kg PBN administration on days 0–7 had no effect
on the development of paclitaxel-induced mechanical hypersen-
sitivity, whereas daily 200 mg/kg PBN administration on days 7–
15 prevented the development of paclitaxel-induced mechanical
hypersensitivity [33]. In comparison, here we have shown that
daily 50 mg/kg PBN administration for two weeks starting one
day before the first dose of paclitaxel (day 21) through to day 13
prevented the development of mechanical hypersensitivity to von
Frey 4 g and 8 g and significantly attenuated mechanical
hypersensitivity to von Frey 15 g. Comparing our results to Kim
et al., suggests that lower doses of PBN over a longer dosing period
that start prior to paclitaxel exposure could be as effective as much
higher doses of PBN after the paclitaxel exposure. Alternatively,
the timing of systemic PBN administration in relation to the
paclitaxel administration could be more functionally important
than dosage. In this case, comparison of the two studies suggests
that the week immediately following the end of the paclitaxel
dosing (day 7–13) is the crucial period to prevent the emergence of
paclitaxel-induced mechanical hypersensitivity. Therefore, poten-
tially paclitaxel-induced ROS during this time period evokes
changes in the nociceptive system that initiate the paclitaxel-
induced pain syndrome, shown to persist for 5 months in this
model [28].
The causal mechanism(s) for chemotherapy-induced painful
peripheral neuropathy are unclear. Various rodent models of
paclitaxel-induced painful peripheral neuropathy have been
reported using different systemic dosing schedules and cumulative
doses of paclitaxel [30,34,35,36,37,38]. The consensus of these
studies is similar to the clinical scenario, in that the degree of
Figure 5. Effect of PBN or TEMPOL on established paclitaxel-
induced cold hypersensitivity. Graph shows the effect of systemic
100 mg/kg PBN, 100 mg/kg TEMPOL or vehicle administration on
behavioural responses to acetone stimulation on day 27/30 following
paclitaxel initiation. Data shown is the median cold score 6
interquartile range after paclitaxel but before PBN/TEMPOL/vehicle
injection (Post Pacl./Pre inj.), and then 1, 3 and 24 hours following
administration of PBN/TEMPOL/vehicle. *p,0.05; Kruskal-Wallis with
Dunn’s Multiple Comparisons post-hoc analysis compared to vehicle-
treated control, n=8 per group.
doi:10.1371/journal.pone.0025212.g005
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paclitaxel administered. The low doses of paclitaxel used here to
evoke paclitaxel-induced pain, do not cause axonal degeneration
demonstrated by morphological analysis of peripheral nerves and
ATF3 expression in dorsal root ganglia [28,30]. However atypical
(swollen and vacuolated) mitochondria in peripheral sensory axons
[28,39] and a loss of intraepidermal nerve fibres [40,41] occur as
the paclitaxel-induced pain syndrome develops. These patholog-
ical changes can be prevented pharmacologically in concert with
the paclitaxel-induced pain syndrome suggesting a causal role for
both phenomena in the aetiology of paclitaxel-induced painful
peripheral neuropathy. Acetyl-L-carnitine has been shown to
prevent the development of paclitaxel-induced pain [32] and the
paclitaxel-induced increase in atypical mitochondria in C-fibres,
but not the paclitaxel-induced loss of intraepidermal nerve fibres
[39]. Minocycline has been shown to prevent the development of
paclitaxel-induced pain [42] and prevent paclitaxel-induced loss of
intraepidermal nerve fibres [41].
The inhibitory effects of a non-specific ROS scavenger reported
here indicate that ROS has a causal role in paclitaxel-induced
pain. While we have provided evidence to suggest superoxide
radicals do not play a major role in paclitaxel-induced painful
peripheral neuropathy, further study could address the contribu-
tion of other free radicals such as hydrogen peroxide, peroxynitrite
and hydroxyl radicals. Considering that mitochondria are a major
source of ROS, this perhaps demonstrates a consequential
mechanism of how the atypical mitochondria in peripheral
sensory axons lead to paclitaxel-induced pain. Alternatively, as
superoxide radicals are predominantly derived from mitochondria,
it is possible that the ROS responsible for paclitaxel-induced pain
are generated from other sites in the cell. In this model of
paclitaxel-induced painful peripheral neuropathy, atypical mito-
chondria were observed at day 7 (where no pain behaviour is
observed) and day 27 (peak pain severity) [28] and PBN
administration between days 7–13 appears to prevent the
emergence of paclitaxel-induced mechanical hypersensitivity as
previously discussed. This could open up the intriguing possibility
that the paclitaxel-induced increase in atypical mitochondria is a
consequence of ROS generation as opposed to the cause of ROS
generation.
In conclusion, this study demonstrates that global inhibition of
ROS can inhibit established paclitaxel-induced pain and prevent
the development of paclitaxel-induced pain, whereas selective
inhibition of superoxide radicals was mostly ineffective. The causal
role of ROS in paclitaxel-induced painful peripheral neuropathy
highlights a potential novel therapeutic strategy for the prevention
and treatment of this major dose-limiting side-effect.
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